Oleoylethanolamide mitigates cardiometabolic disruption secondary to obesity induced by high-fat diet in mice

This publication has 68 references indexed in Scilit:

• Molecular mechanisms and therapeutic perspectives of peroxisome proliferator‐activated receptor α agonists in cardiovascular health and disease
  Medicinal Research Reviews, 2023
• Characterizing Adrenergic Regulation of Glucose Transporter 4-Mediated Glucose Uptake and Metabolism in the Heart
  JACC: Basic To Translational Science, 2023
• Peroxiredomin-4 ameliorates lipotoxicity-induced oxidative stress and apoptosis in diabetic cardiomyopathy
  Biomedicine & Pharmacotherapy, 2021
• WY14643 improves left ventricular myocardial mitochondrial and systolic functions in obese rats under chronic persistent hypoxia via the PPARα pathway
  Life Sciences, 2021
• Expression of NF‐κB, IL‐6, and IL‐10 genes, body composition, and hepatic fibrosis in obese patients with NAFLD—Combined effects of oleoylethanolamide supplementation and calorie restriction: A triple‐blind randomized controlled clinical trial
  Journal of Cellular Physiology, 2020
• Oleoylethanolamide: A novel pharmaceutical agent in the management of obesity‐an updated review
  Journal of Cellular Physiology, 2018
• Enhancing metabolomics research through data mining
  Journal of Proteomics, 2015
• Modulation of excitability, membrane currents and survival of cardiac myocytes by N-acylethanolamines
  Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2012
• Autophagy in cardiac myocyte homeostasis, aging, and pathology
  Cardiovascular Research, 2005
• Oleoylethanolamide, an endogenous PPAR-α agonist, lowers body weight and hyperlipidemia in obese rats
  Neuropharmacology, 2005